logo-loader
viewOpen Orphan PLC

Shareholders approve Venn Life Sciences PLC / Open Orphan merger

Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of Open Orphan spoke to Proactive London's Andrew Scott following a general meeting to approve the merger of the two companies.

Friel, a co-founder of Amryt Pharma PLC (LON:AMYT), former chairman of Fastnet Oil & Gas for five years, and now chief executive of Venn, set up Open Orphan two years ago.

He and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

Quick facts: Open Orphan PLC

Price: 14.25 GBX

AIM:ORPH
Market: AIM
Market Cap: £78.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan's Cathal Friel on its £12mln raise to accelerate coronavirus...

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing they've raised approximately £12mln to ramp up its coronavirus (COVID-19) antiviral testing. Friel says the fundraise has brought many new leading blue-chip institutional shareholders to their...

2 days, 18 hours ago

2 min read